The hollow fibre model in cancer drug screening

the NCI experience


      The in vivo hollow fibre model was developed by the National Cancer Institute (NCI) in the United States of America (USA) at a time when the number of potential anti-cancer drugs arising from in vitro screening efforts exceeded the available capacity for testing in traditional xenograft models. Updated analysis of the predictive value of the hollow fibre model continues to indicate that the greater the response in the hollow fibre assay, the more likely it is that activity will be seen in subsequent xenograft models. The original 12 cell line hollow fibre panel has been supplemented with histology-specific panels, and we begin here to analyse their utility in predicting activity in subsequent in vivo models. The key goal of using the hollow fibre model as a way to decrease the cost, both financial and in the number of animals used, to evaluate initial evidence of a compound's capacity to act across physiological barriers continues to be reinforced with our enlarging experience.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Monks A.
        • Scudiero D.
        • Skehan P.
        • et al.
        Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
        J. Natl. Cancer Inst. 1991; 83: 757-766
        • Paull K.D.
        • Shoemaker R.H.
        • Hodes L.
        • et al.
        Display and analysis of patterns of differential activity of drugs against human tumor cell lines.
        J. Natl. Cancer Inst. 1989; 81: 1088-1092
        • Hollingshead M.G.
        • Alley M.C.
        • Camalier R.F.
        • et al.
        In vivo cultivation of tumor cells in hollow fibers.
        Life Sci. 1995; 57: 131-141
        • Johnson J.I.
        • Decker S.
        • Zaharevitz D.
        • et al.
        Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
        Brit. J. Cancer. 2001; 84: 1424-1431
        • Phillips R.M.
        • Pearce J.
        • Loadman P.M.
        • et al.
        Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells.
        Cancer Res. 1998; 58: 5263-5266
        • Hall L.A.
        • Krauthauser C.M.
        • Wexler R.S.
        • Hollingshead M.G.
        • Slee A.M.
        • Kerr J.S.
        The hollow fiber assay.
        Anticancer Res. 2000; 20: 903-911
        • Alley M.C.
        • Pacula-Cox C.M.
        • Hursey M.L.
        • Rubinstein L.R.
        • Boyd M.F.
        Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.
        Cancer Res. 1991; 51: 1247-1256
        • Sausville E.A.
        • Feigal E.
        Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.
        Ann. Oncol. 1999; 10: 1287-1291
        • Hollingshead M.G.
        • Bonomi C.A.
        • Borgel S.D.
        • et al.
        A potential role for imaging technology in anticancer efficacy evaluations.
        Eur. J. Cancer. 2004; 40 (this issue): 6